hydroxyflutamide has been researched along with calcitriol in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hashimoto, Y; Makishima, M; Nakamura, M | 1 |
Lou, YR; Nazarova, N; Pennanen, P; Qiao, S; Tuohimaa, P | 1 |
Lou, YR; Nazarova, N; Talonpoika, R; Tuohimaa, P | 1 |
3 other study(ies) available for hydroxyflutamide and calcitriol
Article | Year |
---|---|
Development of silicon-containing bis-phenol derivatives as androgen receptor antagonists: selectivity switching by C/Si exchange.
Topics: Androgen Receptor Antagonists; Cell Line, Tumor; Cell Proliferation; HEK293 Cells; Humans; Phenol; Receptors, Androgen; Receptors, Calcitriol; Silicon | 2013 |
Inhibition of fatty acid synthase expression by 1alpha,25-dihydroxyvitamin D3 in prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Calcitriol; Cerulenin; Cycloheximide; Down-Regulation; Enzyme Inhibitors; Fatty Acid Synthases; Flutamide; Gene Expression Regulation, Neoplastic; Humans; Male; Nitriles; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Protein Synthesis Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tosyl Compounds; Tumor Cells, Cultured | 2003 |
5alpha-dihydrotestosterone inhibits 1alpha,25-dihydroxyvitamin D3-induced expression of CYP24 in human prostate cancer cells.
Topics: Androgen Receptor Antagonists; Androgens; Anilides; Calcitriol; Cycloheximide; Cytochrome P-450 Enzyme System; Dihydrotestosterone; Drug Interactions; Flutamide; Gene Expression Regulation, Enzymologic; Humans; Male; Nitriles; Prostatic Neoplasms; Protein Synthesis Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Steroid Hydroxylases; Tosyl Compounds; Tumor Cells, Cultured; Vitamin D3 24-Hydroxylase | 2005 |